Kairos Pharma shares surge 10.68% premarket on positive Phase 2 trial results for ENV105 in prostate cancer showing 86% clinical benefit and 13.7-month median progression-free survival.

Kairos Pharma (NYSE American: KAPA) rose 10.68% in premarket trading following the release of positive interim results from its Phase 2 trial of ENV105 in combination with apalutamide for metastatic prostate cancer. The trial demonstrated clinical benefit in 86% of treated patients, with 13.7 months of median progression-free survival and no dose-limiting toxicities. The findings, presented at the European Society for Medical Oncology (ESMO) Congress, highlight ENV105’s potential to enhance standard care efficacy while maintaining tolerability. The company also noted continued enrollment in its trial across leading U.S. cancer centers and reiterated 2026 milestones, including peer-reviewed publication of data and partnership pursuits. Analyst H.C. Wainwright reaffirmed a Buy rating with a $12.00 price target, underscoring market confidence in Kairos’s advancing pipeline and clinical progress.